Telecoms.com Intelligence's Annual Industry Survey Highlights Increasing Importance Of 'Designed-For' B2B BSS Solutions
16.12.2019 12:00:00 EET | Business Wire | Press release
MDS Global Ltd, a leading BSS-as-a-Service provider, in collaboration with Telecoms.com Intelligence, today announced the findings of their 2019 Annual Industry Survey Report. In the report, dedicated and designed-for modern B2B BSS solutions were highlighted as a key requirement by Communication Service Providers (CSPs), with 84% of respondents identifying B2B as the area where enterprise customers will generate the highest revenue growth in 2020 and beyond.
Based on 540 responses to a survey, the report took an overview of the industry landscape over the last 12 months and provided projections for activity from 2020 and beyond. The OSS/BSS section of the survey highlighted that the B2B segments, including large enterprises (30%), small- and medium-sized enterprises (SMEs) (19%), small office/home office (SOHO) (17%), as well as public sector and wholesale partners, need to be served by a specialist B2B BSS platform. This platform should offer a dedicated digital engagement approach supporting personalised order, workflow and service management demands of enterprises, resellers and partners.
According to the survey, 50% of CSPs already have a separate platform to reflect this sector's demand, and 50% of these require a more digital approach to market engagement. 90% of CSPs agreed that the SME segment specifically requires real-time usage and control and the ability to configure, price and order services via online tools. Defined by service level agreements, business customers often demand higher levels of customisation, shorter time to market for new services, and tend to be less tolerant of failures. But at the same time, they are also less sensitive to price, compared with the consumer market.
Flexibility and customisation for both CSPs and enterprise is also especially important in 5G with its strong virtualisation and software-centric characteristics. The B2B sector is forecast to significantly outweigh the B2C sector as a major source of revenue from 5G services and the report reinforced how important 5G technology is in shaping and scheduling future projects. A staggering 97% of CSPs will use SDN/NFV environments to allow integrated services to be personalised, demonstrating that virtualisation will trigger major BSS change.
Gary Bunney, CEO, MDS Global said, "Currently, most BSS running in Communication Service Providers are hardwired to support traditional enterprise services and incorporate many offline business processes that require high-cost specialist resources to deliver constant change."
He continues, "Today’s market demands low-cost service agility. MDS Global is uniquely placed to assist CSPs in automating service engagement whilst enabling the opportunity that 5G and service personalisation brings to enterprises. We provide a dedicated B2B BSS-as-a-Service platform, decreasing the costs associated with operations, automating customer engagement and providing agility to ensure our CSP customers are able to invent, tailor and launch new services without the hindrance of engineering challenges."
MDS Global's B2B-on-Demand enables cost-efficiency and dedicated service delivery. Download the Telecoms.com Insight 2019 Annual Industry Survey here.
About MDS Global
MDS Global, a leading BSS-as-a-Service provider of VNO, B2B and IoT solutions, look after all aspects of monetisation, assurance and customer steering for complex products and services. We offer a digital operating model in a DevOps context, which enhances stakeholder experiences and provides unprecedented business agility.
Headquartered in the UK, MDS Global’s customers include BT Enterprise (UK), eir (Ireland), iD Mobile from Dixons Carphone (UK), TalkTalk (UK), Telefónica (UK), Vodafone (Germany, Greece and NL), Orange (Belgium), KPN (Netherlands) and Telia (Denmark).
For further information: www.mdsglobal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191216005010/en/
Contact information
Martine Naughton
MDS Global
Email: martine.naughton@mdsglobal.com
Tel: +44 (0) 7909 475815
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom